Literature DB >> 33786915

Voxel-level Classification of Prostate Cancer on Magnetic Resonance Imaging: Improving Accuracy Using Four-Compartment Restriction Spectrum Imaging.

Christine H Feng1, Christopher C Conlin2, Kanha Batra3, Ana E Rodríguez-Soto2, Roshan Karunamuni1, Aaron Simon1, Joshua Kuperman2, Rebecca Rakow-Penner2, Michael E Hahn2, Anders M Dale2, Tyler M Seibert1,2,4.   

Abstract

BACKGROUND: Diffusion magnetic resonance imaging (MRI) is integral to detection of prostate cancer (PCa), but conventional apparent diffusion coefficient (ADC) cannot capture the complexity of prostate tissues and tends to yield noisy images that do not distinctly highlight cancer. A four-compartment restriction spectrum imaging (RSI4 ) model was recently found to optimally characterize pelvic diffusion signals, and the model coefficient for the slowest diffusion compartment, RSI4 -C1 , yielded greatest tumor conspicuity.
PURPOSE: To evaluate the slowest diffusion compartment of a four-compartment spectrum imaging model (RSI4 -C1 ) as a quantitative voxel-level classifier of PCa. STUDY TYPE: Retrospective.
SUBJECTS: Forty-six men who underwent an extended MRI acquisition protocol for suspected PCa. Twenty-three men had benign prostates, and the other 23 men had PCa. FIELD STRENGTH/SEQUENCE: A 3 T, multishell diffusion-weighted and axial T2-weighted sequences. ASSESSMENT: High-confidence cancer voxels were delineated by expert consensus, using imaging data and biopsy results. The entire prostate was considered benign in patients with no detectable cancer. Diffusion images were used to calculate RSI4 -C1 and conventional ADC. Classifier images were also generated. STATISTICAL TESTS: Voxel-level discrimination of PCa from benign prostate tissue was assessed via receiver operating characteristic (ROC) curves generated by bootstrapping with patient-level case resampling. RSI4 -C1 was compared to conventional ADC for two metrics: area under the ROC curve (AUC) and false-positive rate for a sensitivity of 90% (FPR90 ). Statistical significance was assessed using bootstrap difference with two-sided α = 0.05.
RESULTS: RSI4 -C1 outperformed conventional ADC, with greater AUC (mean 0.977 [95% CI: 0.951-0.991] vs. 0.922 [0.878-0.948]) and lower FPR90 (0.032 [0.009-0.082] vs. 0.201 [0.132-0.290]). These improvements were statistically significant (P < 0.05). DATA
CONCLUSION: RSI4 -C1 yielded a quantitative, voxel-level classifier of PCa that was superior to conventional ADC. RSI classifier images with a low false-positive rate might improve PCa detection and facilitate clinical applications like targeted biopsy and treatment planning. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 2.
© 2021 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  diffusion magnetic resonance imaging; prostate cancer; prostate cancer detection; restriction spectrum imaging

Mesh:

Year:  2021        PMID: 33786915      PMCID: PMC8363567          DOI: 10.1002/jmri.27623

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   5.119


  41 in total

1.  A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)-biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy.

Authors:  Yipeng Hu; Hashim U Ahmed; Tim Carter; Nimalan Arumainayagam; Emilie Lecornet; Winston Barzell; Alex Freeman; Pierre Nevoux; David J Hawkes; Arnauld Villers; Mark Emberton; Dean C Barratt
Journal:  BJU Int       Date:  2012-03-06       Impact factor: 5.588

2.  Novel technique for characterizing prostate cancer utilizing MRI restriction spectrum imaging: proof of principle and initial clinical experience with extraprostatic extension.

Authors:  R A Rakow-Penner; N S White; J K Parsons; H W Choi; M A Liss; J M Kuperman; N Schenker-Ahmed; H Bartsch; R F Mattrey; W G Bradley; A Shabaik; J Huang; D J A Margolis; S S Raman; L Marks; C J Kane; R E Reiter; D S Karow; A M Dale
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-01-06       Impact factor: 5.554

3.  What is the optimal b value in diffusion-weighted MR imaging to depict prostate cancer at 3T?

Authors:  T Metens; D Miranda; J Absil; C Matos
Journal:  Eur Radiol       Date:  2011-10-05       Impact factor: 5.315

4.  Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study.

Authors:  Aritrick Chatterjee; Roger M Bourne; Shiyang Wang; Ajit Devaraj; Alexander J Gallan; Tatjana Antic; Gregory S Karczmar; Aytekin Oto
Journal:  Radiology       Date:  2018-02-02       Impact factor: 11.105

5.  Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer.

Authors:  Kinzya B Grant; Harsh K Agarwal; Joanna H Shih; Marcelino Bernardo; Yuxi Pang; Dagane Daar; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Abdom Imaging       Date:  2015-03

Review 6.  Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2.

Authors:  Baris Turkbey; Andrew B Rosenkrantz; Masoom A Haider; Anwar R Padhani; Geert Villeirs; Katarzyna J Macura; Clare M Tempany; Peter L Choyke; Francois Cornud; Daniel J Margolis; Harriet C Thoeny; Sadhna Verma; Jelle Barentsz; Jeffrey C Weinreb
Journal:  Eur Urol       Date:  2019-03-18       Impact factor: 20.096

7.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

Review 8.  MR-guided biopsy and focal therapy: new options for prostate cancer management.

Authors:  Fuad F Elkhoury; Demetrios N Simopoulos; Leonard S Marks
Journal:  Curr Opin Urol       Date:  2018-03       Impact factor: 2.808

9.  High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness.

Authors:  Tsutomu Tamada; Naoki Kanomata; Teruki Sone; Yoshimasa Jo; Yoshiyuki Miyaji; Hiroki Higashi; Akira Yamamoto; Katsuyoshi Ito
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

10.  Prostate Stereotactic Body Radiation Therapy With a Focal Simultaneous Integrated Boost: Acute Toxicity and Dosimetry Results From a Prospective Trial.

Authors:  Andrew M McDonald; Michael C Dobelbower; Eddy S Yang; Grant M Clark; Rojymon Jacob; Robert Y Kim; Rex A Cardan; Richard Popple; Jeffrey W Nix; Soroush Rais-Bahrami; John B Fiveash
Journal:  Adv Radiat Oncol       Date:  2018-09-19
View more
  1 in total

1.  Correcting B0 inhomogeneity-induced distortions in whole-body diffusion MRI of bone.

Authors:  Leonardino A Digma; Christine H Feng; Christopher C Conlin; Ana E Rodríguez-Soto; Allison Y Zhong; Troy S Hussain; Asona J Lui; Kanha Batra; Aaron B Simon; Roshan Karunamuni; Joshua Kuperman; Rebecca Rakow-Penner; Michael E Hahn; Anders M Dale; Tyler M Seibert
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.